Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Deciding between Multiple Curative Options in Sickle Cell Disease: Cost-Effectiveness of Non-Myeloablative/Reduced Intensity Conditioning Haploidentical Allo-HSCT Vs Gene Therapy Vs Standard of Care in Adult Patients with Sickle Cell Disease

Karthik Chetlapalli, Ayesha Butt, Satoko Ito, Daniel Wang, Cecelia Calhoun, Lakshmanan Krishnamurti, Ankur Pandya, George Goshua

Blood (2024) 144 (Supplement 1): 601.

https://doi.org/10.1182/blood-2024-203234

Published: 2024

Journal Articles

Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States

George Goshua, Satoko Ito, Karthik Chetlapalli, Kunal C Potnis, Cecelia Calhoun, Lakshmanan Krishnamurti, Harlan M. Krumholz, Ankur Pandya

Blood (2023) 142 (Supplement 1): 490.

https://doi.org/10.1182/blood-2023-191072

Published: 2023

Journal Articles

Pola-R-CHP for DLBCL: cost-effective at first glance

Edward R. Scheffer Cliff, Ankur Pandya

Blood (2022) 140 (25): 2654–2655.

https://doi.org/10.1182/blood.2022017342

Published: 2022

Journal Articles

A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease

George Goshua, Ronald G. Hauser, Chris Tormey, Ankur Pandya, Jeanne E. Hendrickson

Blood (2022) 140 (Supplement 1): 2147–2148.

https://doi.org/10.1182/blood-2022-169099

Published: 2022

Journal Articles

Gene Therapy Equity in Sickle Cell Disease: Distributional Cost-Effectiveness Analysis (DCEA) of Gene Therapy Vs. Standard-of-Care in Patients with Sickle Cell Disease in the United States

George Goshua, Cecelia Calhoun, Vivien Cheng, Lyndon James, Andrea Luviano, Lakshmanan Krishnamurti, Ankur Pandya

Blood (2022) 140 (Supplement 1): 1395–1396.

https://doi.org/10.1182/blood-2022-157460

Published: 2022

Journal Articles

Cost-Effectiveness of Posaconazole vs Fluconazole in the Prevention of Invasive Fungal Infections among Patients with Graft-Versus-Host Disease (GVHD) in the US.

Amy K. O’Sullivan, PhD, Milton C. Weinstein, PhD, Ankur Pandya, MPH, David Thompson, PhD, Amelia Langston, MD, John Perfect, MD, George Papadopoulos

Blood (2007) 110 (11): 3336.

https://doi.org/10.1182/blood.V110.11.3336.3336

Published: 2007

Journal Articles

Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S.

Amy K. O’Sullivan, PhD, Ankur Pandya, MPH, David Thompson, PhD, George Papadopoulos, BSc, Milton C. Weinstein, PhD, John R. Perfect, MD, Amelia Langston, MD

Blood (2006) 108 (11): 3311.

https://doi.org/10.1182/blood.V108.11.3311.3311

Published: 2006

NARROW

Deciding between Multiple Curative Options in Sickle Cell Disease: Cost-Effectiveness of Non-Myeloablative/Reduced Intensity Conditioning Haploidentical Allo-HSCT Vs Gene Therapy Vs Standard of Care in Adult Patients with Sickle Cell Disease

Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States

Pola-R-CHP for DLBCL: cost-effective at first glance

A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease

Gene Therapy Equity in Sickle Cell Disease: Distributional Cost-Effectiveness Analysis (DCEA) of Gene Therapy Vs. Standard-of-Care in Patients with Sickle Cell Disease in the United States

Cost-Effectiveness of Posaconazole vs Fluconazole in the Prevention of Invasive Fungal Infections among Patients with Graft-Versus-Host Disease (GVHD) in the US.

Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S.

Email alerts

ASH Publications

American Society of Hematology

Deciding between Multiple Curative Options in Sickle Cell Disease: Cost-Effectiveness of Non-Myeloablative/Reduced Intensity Conditioning Haploidentical Allo-HSCT Vs Gene Therapy Vs Standard of Care in Adult Patients with Sickle Cell Disease

Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States

Pola-R-CHP for DLBCL: cost-effective at first glance

A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease

Gene Therapy Equity in Sickle Cell Disease: Distributional Cost-Effectiveness Analysis (DCEA) of Gene Therapy Vs. Standard-of-Care in Patients with Sickle Cell Disease in the United States

Cost-Effectiveness of Posaconazole vs Fluconazole in the Prevention of Invasive Fungal Infections among Patients with Graft-Versus-Host Disease (GVHD) in the US.

Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only